Category
Tga
8 articles
Telehealth Prescribing of Schedule 4 Peptides: 2026 Brief
Telehealth is permanent in Australian healthcare, but its overlap with Schedule 4 peptide prescribing is under-examined. The framework, gaps, and priorities.
Vaping Reform in Australia 2026: A Policy Analysis
Australia's prescription-only vaping model, the 2024 pharmacy supply amendments, patchy enforcement, and youth uptake inside the 2026 harm-reduction debate.
TGA Reform Priorities for 2027: Faster Medicine Access
Australia's TGA faces pressure to modernise approvals, lift biosimilar uptake, close the digital therapeutics gap, and strengthen surveillance by 2027.
Compounding Pharmacy Regulation in Australia: TGA Tension
Section 19A lets compounders fill GLP-1 shortages, but BPC-157's Schedule 4 move and Pharmacy Board scrutiny expose a growing access-versus-safety tension.
TGA Peptide Regulation in Australia: A Practical Guide
The TGA classifies peptides under a complex scheduling framework. Peptide schedules, the June 2024 BPC-157 reclassification, and what 'research use' means.
BPC-157 and Schedule 4: Australia's TGA Rules Explained
In June 2024 the TGA moved BPC-157 to Schedule 4. This analysis unpacks the rationale, what changed for patients and pharmacies, and what evidence shows.
GLP-1 Shortages in Australia: Policy Failures Exposed
Australia's GLP-1 shortage exposes deep gaps in medicines policy. The supply crisis, access inequities, the compounding debate, and six reforms needed.
Medicare and PBS Reform for Obesity Treatment in Australia
Australia's PBS coverage of obesity medication lags the clinical evidence and leaves treatment inequitable. The case for expanded GLP-1 listing and reform.